Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular biology, mechanism, and preclinical animal studies with no original human clinical data.
PubMed 27048303 · doi:10.1101/cshperspect.a025924
What was done
This review examined the molecular biology, physiological mechanisms, and preclinical evidence surrounding rapamycin and mechanistic target of rapamycin (mTOR) pathway inhibition as an antiaging intervention, along with potential strategies to mitigate side effects.
What was found
The abstract provides no quantitative data or specific numerical effect sizes. It reports that genetic and pharmacological inhibition of the mTOR nutrient-sensing pathway extends lifespan across multiple model organisms, including yeast, worms, flies, and mice.
Why it matters
It outlines how targeting the central nutrient-sensing mTOR kinase may slow biological aging and highlights the translational challenge of balancing efficacy with clinical side effects.
Limits
The abstract describes a narrative review without systematic search criteria or meta-analytic data. All longevity findings noted are from non-human model organisms, and no human clinical efficacy or safety endpoints are quantified.
Cited by
- supports Dampening TOR kinase activity either genetically or with rapamycin extends lifespan in yeast, worms, flies, and mice.